Clinical Trials Logo

Chordoma clinical trials

View clinical trials related to Chordoma.

Filter by:

NCT ID: NCT00150072 Completed - Chordoma Clinical Trials

Efficacy and Safety of Imatinib in Chordoma

Start date: October 2004
Phase: Phase 2
Study type: Interventional

Preliminary response data, observed by Casali (Cancer, 2004) with imatinib 800 mg/day in patients affected by chordoma, need to be confirmed by a Phase II study, whose primary endpoint will be the formal assessment of clinical and pathological response. Aim of the study will be to explore treatment's activity, but also the potential impact of tumor response, the feasibility and outcome of subsequent surgery and radiotherapy. In addition, patterns of tumour response need to be investigated as well, given the peculiar patterns of response shown with molecular-targeted therapy in solid tumors.